From research to treatment

Céline Giustranti
06/22/2017
Share
Accelerating the process that leads from scientific innovation to better care for patients is the aim of Institut Curie. This goal perfectly illustrates translational research and clinical research.
recherche-labo2

Through its institutional plan, Institut Curie aims to build the Comprehensive Cancer Center of the future. Institut Curie has taken on board all of the recent progress in precision medicine, immunotherapy and epigenetics, and plans to adapt and restructure to offer its patients the benefits of these discoveries.

To achieve this, Institut Curie can rely on its solid foundation of scientific and medical excellence, and the humane approach of our teams. These values have been passed down to us by the most brilliant pioneers in the fight against cancer, Pierre and Marie Curie, who have inspired us for over a century.

Translational research, the first step toward clinical application

Like a catalyst, translational research brings doctors and researchers together to transform basic research discoveries into clinical applications. The aim of the translational research department is to accelerate the process that leads from scientific innovation to better care for patients. It provides the clinicians and researchers of Institut Curie with the human and technological means needed to develop applied projects in diagnosis or treatment of cancer. The department was created in 2003 and is today headed by Sergio Roman-Roman. Its goal is to promote collaborative projects that involve researchers and doctors, and so to transform scientific discoveries into applications for patients.

However, translational research extends well beyond the eponymous department through the development of a common culture, language and expertise, as evidenced by the medical-scientific program.

Our commitments

  • Promote original cooperation in all laboratories in a spirit of openness to our outside partners.
  • Develop a common culture between doctors and researchers.

Deploying clinical research

Innovation is not enough. We also need medical projects that benefit as many patients as possible. Everyone should have access to the progress of research.

At Institut Curie, almost one in five patients is already part of an interventional clinical trial, and this figure is set to increase in the coming years, with a goal of 30% by 2020.

The institute is widely recognized for its ability to innovate and apply scientific progress at the patient’s bedside. It has received the following distinctions affirming this:

"Direction de la recherche clinique et de l’innovation (DRCI)" certification, issued by the French ministry for health, awarded for its clinical-trial promotion activities.

• "Centre de Recherche clinique (CRC)" certification, issued by the minister for its investigation activities.

"Centre d’essais cliniques de phase précoce (CLIP²)" certification from INCa for early-phase trials in adults and in children.

SiRIC certification as an integrated cancer research site, also under the auspices of the INCa.

Institut Curie has always fostered a continuum between clinical care and research, just as Marie Curie envisioned it. Its medical and scientific program aims to strengthen these interactions between basic, clinical and translational research.

Our commitments

Offering patients the best care entails developing state-of-the-art technologies.

In this respect, Institut Curie undertakes to:

• Continue to innovate in radiotherapy.

• Deploy an interventional radiology technical platform.

• Include one of every three patients in clinical trials.

• Develop genomic medicine.

• Provide access to genetic and molecular oncology.

Testing for all patients in the Ile-de-France region.

5
translational research teams with SIRIC certification.
40
beds ultimately dedicated to early trials